Retrospective cohort adds recombinant BNP to levosimendan in refractory heart failure
A single-center study reports short-term outcomes for the combination in patients who had not responded to standard heart failure therapy.
PR
By Priya Raman · Science Reporter
Oct 24 03:00 ETSource: springermedicine.com
The wire
- 01Investigators retrospectively compared short-term outcomes in refractory heart failure patients given recombinant human brain natriuretic peptide alongside levosimendan at a single center.
- 02Recombinant BNP is an approved peptide therapeutic, and combination use with inotropes is an off-label practice question for cardiology and hospital pharmacy.
- 03Single-center retrospective design with no randomization limits causal inference; full effect sizes and sample size are not stated in the available summary.
From the source
Read at springermedicine.comShort-term outcomes of recombinant human brain natriuretic peptide added to levosimendan in patients with refractory heart failure: a single-center retrospective cohort study
